Franco Lombardo, PhD

Bio

Dr. Lombardo primary interests and areas of expertise reside in ADME/physicochemical properties determination and modeling, in vitro, in vivo and in silico. He has co-authored over 50 research publications and book chapters, as well as presented invited lectures and seminars at Universities and industrial conferences worldwide.

After 3 years at Merck Research Laboratories, in the pre-formulation group within Pharmaceutical Research and Development in West Point PA,Dr. Lombardo moved to Pfizer in Groton, CT. He started in the Early Candidates Group in Pharmaceutical Research and Development working on physicochemical and formulation aspects in close contact with Discovery scientists. He then joined Pfizer Discovery in 1998, as a member of the Molecular Properties Group, sharing responsibilities with Dr. Chris Lipinski, focusing on physicochemical properties and their applications to ADME, ranging from methods development to in silico application.

In 2006 he moved to the Novartis Institutes for Biomedical Research, within the Metabolism and Pharmacokinetics group in Cambridge, MA. His primary work was on PK characterization as project team member and supervisor of the disease area team members largely in Oncology, with some involvement in Infectious Diseases and Ophthalmology.

In October 2014 he accepted a position at Biogen where he maintained his involvement with and interest in PK and physicochemical properties with a very significant ADME modeling component.

In January 2017, he joined Alkermes where he was the head of the DMPK Group, within Clinical Research, with responsibilities spanning Discovery and Development. In May 2021, he started a PK consulting firm (CMAXDMPK, LLC). He held an Affiliate Research Professorship appointment at Northeastern University Department of Chemistry and Chemical Biology from August 2019.